Matches in SemOpenAlex for { <https://semopenalex.org/work/W3088230839> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W3088230839 endingPage "S750" @default.
- W3088230839 startingPage "S750" @default.
- W3088230839 abstract "Talimogene laherparepvec (T-VEC) is a genetically modified herpes simplex type 1 virus and known as an effective oncolytic immunotherapy for injectable cutaneous, subcutaneous and nodal melanoma lesions in stage IIIB-IVM1a patients, as approved by the European Medicines Agency (EMA). The objective of the current study was to identify prognostic factors for achieving a complete response (CR) that can be used to select patients for treatment with T-VEC monotherapy. Patients with stage IIIB-IVM1a melanoma, treated with T-VEC at the Netherlands Cancer Institute between 2016-12 and 2019-05 with a follow-up time > 6 months, were included. Data was collected on baseline characteristics, responses and adverse events (AEs). Uni- and multivariable analyses were conducted and a prediction model was developed to identify prognostic factors associated with CR. A total of 71 patients were included with a median age of 68 years (range: 35-90). The median follow-up time was 16.1 months. As best response, 47 patients (66%) had a CR and 10 patients (14%) had a PR, resulting in an overall response rate of 80%. Twenty-one patients (30%) stopped treatment because of progressive disease and 16 patients (32%) developed a recurrence during follow-up after achieving a PR or CR. Median duration of CR was 11 months. The durable response rate (objective response lasting continuously > 6 months) was 42%. Grade 1-2 AEs occurred in almost every patient. Tumor size, type of metastases, prior treatment with systemic therapy and stage (8Th AJCC) were independent prognostic factors for achieving a CR. The prediction model includes the predictors tumor size, type of metastases (only cutaneous vs. subcutaneous (+/- cutaneous) vs. nodal (+/- cutaneous/subcutaneous)) and number of lesions. This study shows that intralesional T-VEC monotherapy for stage IIIB-IVM1a melanoma is able to achieve high complete and durable response rates. The prediction model shows that use of T-VEC in patients with less tumor burden is associated with better outcomes, suggesting T-VEC should perhaps be used earlier in the course of the disease." @default.
- W3088230839 created "2020-10-01" @default.
- W3088230839 creator A5000662102 @default.
- W3088230839 creator A5007717740 @default.
- W3088230839 creator A5009141072 @default.
- W3088230839 creator A5019573174 @default.
- W3088230839 creator A5044990437 @default.
- W3088230839 creator A5058303447 @default.
- W3088230839 creator A5072403971 @default.
- W3088230839 creator A5078183093 @default.
- W3088230839 creator A5091348562 @default.
- W3088230839 creator A5091592473 @default.
- W3088230839 date "2020-09-01" @default.
- W3088230839 modified "2023-09-30" @default.
- W3088230839 title "1112P Intralesional therapy with talimogene laherparepvec for stage IIIB-IVM1a melanoma is able to achieve a high rate of complete and durable responses and is associated with tumour load" @default.
- W3088230839 doi "https://doi.org/10.1016/j.annonc.2020.08.1235" @default.
- W3088230839 hasPublicationYear "2020" @default.
- W3088230839 type Work @default.
- W3088230839 sameAs 3088230839 @default.
- W3088230839 citedByCount "0" @default.
- W3088230839 crossrefType "journal-article" @default.
- W3088230839 hasAuthorship W3088230839A5000662102 @default.
- W3088230839 hasAuthorship W3088230839A5007717740 @default.
- W3088230839 hasAuthorship W3088230839A5009141072 @default.
- W3088230839 hasAuthorship W3088230839A5019573174 @default.
- W3088230839 hasAuthorship W3088230839A5044990437 @default.
- W3088230839 hasAuthorship W3088230839A5058303447 @default.
- W3088230839 hasAuthorship W3088230839A5072403971 @default.
- W3088230839 hasAuthorship W3088230839A5078183093 @default.
- W3088230839 hasAuthorship W3088230839A5091348562 @default.
- W3088230839 hasAuthorship W3088230839A5091592473 @default.
- W3088230839 hasBestOaLocation W30882308391 @default.
- W3088230839 hasConcept C121608353 @default.
- W3088230839 hasConcept C126322002 @default.
- W3088230839 hasConcept C141071460 @default.
- W3088230839 hasConcept C143998085 @default.
- W3088230839 hasConcept C146357865 @default.
- W3088230839 hasConcept C151730666 @default.
- W3088230839 hasConcept C197934379 @default.
- W3088230839 hasConcept C2776694085 @default.
- W3088230839 hasConcept C2777658100 @default.
- W3088230839 hasConcept C2778822529 @default.
- W3088230839 hasConcept C2779134260 @default.
- W3088230839 hasConcept C3019096185 @default.
- W3088230839 hasConcept C502942594 @default.
- W3088230839 hasConcept C71924100 @default.
- W3088230839 hasConcept C82210918 @default.
- W3088230839 hasConcept C86803240 @default.
- W3088230839 hasConceptScore W3088230839C121608353 @default.
- W3088230839 hasConceptScore W3088230839C126322002 @default.
- W3088230839 hasConceptScore W3088230839C141071460 @default.
- W3088230839 hasConceptScore W3088230839C143998085 @default.
- W3088230839 hasConceptScore W3088230839C146357865 @default.
- W3088230839 hasConceptScore W3088230839C151730666 @default.
- W3088230839 hasConceptScore W3088230839C197934379 @default.
- W3088230839 hasConceptScore W3088230839C2776694085 @default.
- W3088230839 hasConceptScore W3088230839C2777658100 @default.
- W3088230839 hasConceptScore W3088230839C2778822529 @default.
- W3088230839 hasConceptScore W3088230839C2779134260 @default.
- W3088230839 hasConceptScore W3088230839C3019096185 @default.
- W3088230839 hasConceptScore W3088230839C502942594 @default.
- W3088230839 hasConceptScore W3088230839C71924100 @default.
- W3088230839 hasConceptScore W3088230839C82210918 @default.
- W3088230839 hasConceptScore W3088230839C86803240 @default.
- W3088230839 hasLocation W30882308391 @default.
- W3088230839 hasOpenAccess W3088230839 @default.
- W3088230839 hasPrimaryLocation W30882308391 @default.
- W3088230839 hasRelatedWork W2054476072 @default.
- W3088230839 hasRelatedWork W2266457985 @default.
- W3088230839 hasRelatedWork W2317102953 @default.
- W3088230839 hasRelatedWork W2351330346 @default.
- W3088230839 hasRelatedWork W2356001539 @default.
- W3088230839 hasRelatedWork W2381351680 @default.
- W3088230839 hasRelatedWork W2418204902 @default.
- W3088230839 hasRelatedWork W2775050055 @default.
- W3088230839 hasRelatedWork W3086536515 @default.
- W3088230839 hasRelatedWork W4281778742 @default.
- W3088230839 hasVolume "31" @default.
- W3088230839 isParatext "false" @default.
- W3088230839 isRetracted "false" @default.
- W3088230839 magId "3088230839" @default.
- W3088230839 workType "article" @default.